Volumetric MRI
Ninety-eight subjects completed the study: 35 (35.7%) neuroEPO plus 0.5 mg, 31 (31.6%) neuroEPO plus 1.0 mg, and 32 (32.7%) placebo. At baseline, the hippocampal (HC) volume measured by MRI was adjusted by estimating the total intracranial volume (eTIV) and it was 2.06 × 10For the three groups at 48 weeks, vMRI showed a decrease in the hippocampal volume. The three groups had a similar global percentage of change: −3.40, −3.26, and −3.32 in the case of neuroEPO plus 0.5 mg, 1.0 mg, and placebo, respectively, The analysis of HC volume perceptual change vs. ADAS-Cog11 initial value for individual subjects (Fig. S4, 